# IIaprazole for the Treatment and Prevention of Peptic Ulcer Bleeding in Chinese Patients

> **NCT03362268** · PHASE2 · COMPLETED · sponsor: **Livzon Pharmaceutical Group Inc.** · enrollment: 180 (actual)

## Conditions studied

- Peptic Ulcer Hemorrhage

## Interventions

- **DRUG:** Ilaprazole
- **DRUG:** omeprazole

## Key facts

- **NCT ID:** NCT03362268
- **Lead sponsor:** Livzon Pharmaceutical Group Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2014-06
- **Final completion:** 2014-07
- **Target enrollment:** 180 (ACTUAL)
- **Last updated:** 2017-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03362268

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03362268, "IIaprazole for the Treatment and Prevention of Peptic Ulcer Bleeding in Chinese Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03362268. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*